GSK is reportedly targeting $55 billion in sales, with the goal unrelated to obesity treatments. However, it is unclear if GSK has made any recent moves to achieve this target, as another company, Novartis, has made a purchase that could be related to a $55 billion market opportunity. The connection between GSK's sales goal and Novartis' actions is not specified.